Compare BGSF & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BGSF | BYSI |
|---|---|---|
| Founded | 2007 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.0M | 58.4M |
| IPO Year | 2013 | 2016 |
| Metric | BGSF | BYSI |
|---|---|---|
| Price | $5.62 | $1.21 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 6.5K | ★ 25.7K |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | ★ 36.04% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $93,310,000.00 | N/A |
| Revenue This Year | $4.67 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.26 | $1.16 |
| 52 Week High | $8.20 | $2.44 |
| Indicator | BGSF | BYSI |
|---|---|---|
| Relative Strength Index (RSI) | 52.43 | 26.58 |
| Support Level | $5.49 | N/A |
| Resistance Level | $5.79 | $1.60 |
| Average True Range (ATR) | 0.14 | 0.13 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 43.49 | 1.91 |
BGSF Inc is a national provider of consulting, managed services, and professional workforce solutions. The company operates in one segment of Property Management, which includes centralized support services through executive, marketing, human resources, information technology, accounting, treasury, and billing operations.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.